HERA-GITRL / Apogenix - LARVOL DELTA

Excellent preclinical efficacy data of Apogenix' HERA-GITRL published in Journal for ImmunoTherapy of Cancer (PharmiWeb) - "Apogenix...announced today that new data published in Journal for ImmunoTherapy of Cancer demonstrate the potent anti-tumor efficacy of Apogenix' HERA-GITRL...Treatment with HERA-GITRL resulted in dose-dependent tumor growth inhibition and increased T cell infiltration in the tumor. Further, it significantly boosted proliferation and differentiation of stimulated T cells while not producing any response in unstimulated T cells."

Preclinical

The novel hexavalent human GITR agonist HERA-GITRL promotes anti-tumor efficacy independent of Fc-functionality and shows superior activity compared with the monoclonal anti-GITR antibody TRX518 (CIMT 2019) - "Glucocorticoid-induced TNFR-related protein (GITR, TNFRSF18, CD357), a TNFR-SF member, is a co-stimulatory receptor that increases anti-tumor T cell activation. A comparison of HERA-GITRL with the anti-GITR antibody TRX518 showed superior agonistic activity of our HERA construct in vitro with and without cross-linking. The HERA-ligand concept has also been successfully translated to HERA-TRAIL (now in Phase I), -CD40L, -CD27L,-LIGHT and -4-1BBL."

Clinical

The novel hexavalent human GITR agonist HERA-GITRL promotes anti-tumor efficacy independent of Fc-functionality and shows superior activity compared with the monoclonal anti-GITR antibody TRX518 (AACR 2019) - "Glucocorticoid-induced TNFR-related protein (GITR, TNFRSF18, CD357), a TNFR-SF member, is a co-stimulatory receptor that increases anti-tumor T cell activation. A comparison of HERA-GITRL with the anti-GITR antibody TRX518 showed superior agonistic activity of our HERA construct in vitro with and without cross-linking. The HERA-ligand concept has also been successfully translated to HERA-TRAIL (now in Phase I), -CD40L, -CD27L,-LIGHT and -4-1BBL."

Clinical